drugset / Trial / NCT06851832
Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older
Phase 1/2
Active not recruiting
960 enrolled
Ab&B Bio-tech Co., Ltd.JS
Yither Biotechnology Co., Ltd · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The objective of this study was to evaluate the safety, immunogenicity and immune persistence of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and older.
Timeline
- Start
- 2025-02-16
- Primary completion
- 2026-09-16
- Completion
- 2028-09-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Zoster Vaccine (CHO Cell) | Vaccine | 0.5 ml | Intramuscular |
| Subject | Recombinant zoster vaccine(CHO cell)(low adjuvant) | Vaccine | 0.5 ml | Intramuscular |
| Comparator | Varivax | Vaccine | 0.5 ml | Subcutaneous |